摘要
目的：通过检测雌激素受体β（estroge nreceptorp，ERβ）在乳腺癌内分泌治疗患者中的表达，探讨ERp表达与临床和内分泌治疗耐药的关系。方法：收集2000—01—01—2010—12—31新疆医科大学第一附属医院乳腺外科诊治的临床资料完整、临床分期为Ⅰ～Ⅱ期、ERa表达阳性、绝经后女性159例，均经病理确诊为浸润性非特殊性乳腺癌，且均口服他莫昔芬进行内分泌治疗。免疫组化法检测乳腺癌组织标本中ERI]的表达，分为阴性组和阳性组，通过临床随访获得无瘤生存时间，应用SPSS17．0统计软件包对数据进行统计学处理，比较临床因素及预后在其不同表达间的差异。结果：ER8表达与原癌基因人类表皮生长因子受体2（human epidermalgrowth factor receptor2，HER-2）表达差异有统计学意义（X^2=4．416，P=0．036），而与年龄、肿瘤大小及淋巴结转移等因素无关，P〉0．05。Kaplan-Meier生存曲线分析提示，ERl3阳性表达无瘤生存率显著下降，明显低于ER8阴性表达，与HER-2生存曲线基本一致；Cox多因素分析结果显示，ERt]、淋巴结转移是预后独立影响因素，且ERI]阳性表达及淋巴结有转移均为危险因素，P〈0．05，OR〈1。结论：ERB阳性表达在乳腺癌内分泌治疗耐药中起重要作用，其阳性表达是内分泌治疗后乳腺癌预后不良指标之一。
OBJECTIVE： To investigate the relationship between ERβ（estrogen receptor beta） and clinical endocrino- therapy resistance by detecting the expression of ERβ in breast cancer patients who were treated with endocrine drugs. METHODS：Totally 159 cases were collected from the First Affiliated Hospital of Xinjiang Medical University between 2000-01-01 and 2010-12-31, which were postmenopausal women and diagnosed by pathology and treated with endocrine drugs. The clinical stage was Ⅰ-- Ⅱ , the expression of ER alpha was positive. The ERβ expression was detected by im- munohistochemistry （IHC）, and divided into negative group and positive group. Disease-free survival time were obtained through the clinical follow-up visit. Using SPSS17.0 statistical software package for statistical data processing, compa- ring the clinical factors and prognosis in the different expression of ERβ. RESULTS： The difference between ERβ expres- sion and HER-2 expression was significant （X^2 =4. 416 ,P=0. 036）. The expression of ERβ had no correlation with age, tumor size and lymph node metastasis （P〉0.05）. The Kapian-Meier survivorship curve showed that the disease-free sur- vival rate of ERβ which was positive expression in breast cancer was dropped significantly and was lower than those of negative expression. This was in step with the expression of HERS. Cox multiple-factor analysis showed that ERβ posi- tive expression and lymph node metastasis were independent prognosis factors （P〈0.05, OR〈1）. CONCLUSIONS.. The positive expression of ERβ plays an important role in endocrinotherapy resistance. It is poor prognosis factors of breast cancer in that ERβ is positive expression.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2014年第8期612-615,625,共5页
Chinese Journal of Cancer Prevention and Treatment
基金
新疆维吾尔自治区自然科学基金(2011211A069)
关键词
乳腺肿瘤
雌激素受体Β
内分泌治疗
耐药
breast neoplasms
estrogen receptor beta
endocrine therapy
drug resistance
